<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02213081</url>
  </required_header>
  <id_info>
    <org_study_id>STU00091840</org_study_id>
    <nct_id>NCT02213081</nct_id>
  </id_info>
  <brief_title>Ulipristal for Endometriosis-related Pelvic Pain</brief_title>
  <official_title>Phase IV Pilot Study of Ulipristal Acetate for Treatment of Endometriosis-related Pelvic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this research is to assess the benefit of a medication (ulipristal) for
      alleviation of symptoms in women with chronic, endometriosis-related pelvic pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will assess the use of a medication to improve symptoms of chronic,
      endometriosis-related pelvic pain among women who did no achieve relief with prior surgical
      and medical treatments.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pelvic Pain</measure>
    <time_frame>5 months</time_frame>
    <description>Patients will document self-reported weekly average pelvic pain scores for one month prior to starting treatment, while receiving treatment for 3 months and for one full month subsequent to treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vaginal bleeding</measure>
    <time_frame>5 months</time_frame>
    <description>Patients will record the # of tampons or pads they use each week while enrolled in the study (1 month pre-medication, 3 months during medication, 1 month after medication).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain with sexual intercourse</measure>
    <time_frame>5 months</time_frame>
    <description>If sexually active, patients will document self-reported weekly average pelvic pain scores with sexual intercourse for one month prior to starting treatment, while receiving treatment for 3 months and for one full month subsequent to treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum hormone levels</measure>
    <time_frame>5 months</time_frame>
    <description>Serum levels of hormones that regulate the menstrual cycle will be assessed one month prior to starting treatment, while receiving treatment for 3 months and at one month subsequent to treatment.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pain with bowel movements</measure>
    <time_frame>5 months</time_frame>
    <description>Patients will document self-reported weekly average pelvic pain scores with defecation for one month prior to starting treatment, while receiving treatment for 3 months and for one full month subsequent to treatment.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>Ulipristal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 patients with chronic, endometriosis-related pelvic pain refractory to medical and/or surgical therapies will receive 15mg ulipristal every other day (three times a week- Monday, Thursday, Saturday) for three months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ulipristal</intervention_name>
    <description>Patients will take 15mg every other day, or every 4 days per week.</description>
    <arm_group_label>Ulipristal</arm_group_label>
    <other_name>Ulipristal Acetate</other_name>
    <other_name>Ella</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of endometriosis with surgical confirmation via laparoscopy performed within
             3 years prior to study enrollment

          -  English-speaking reproductive-age women (18-50yo) with regular, cyclical menses

          -  Treatment-refractory endometriosis, as defined by persistent or recurrent pelvic pain
             following one or more treatments involving surgery and/or hormonal treatment

          -  Dysmenorrhea and chronic pelvic pain for a least one week out of the month during past
             5 months or longer

          -  Endometrial biopsy before and after intervention

          -  Adequate organ and marrow function as defined below:

          -  leukocytes ≥ 3,000/microliter

          -  absolute neutrophil count ≥ 1,500/microliter

          -  platelets ≥ 100,000/microliter

          -  total bilirubin within normal institutional limits

          -  Liver function tests ≤ 2.5 X institutional upper limit of normal

          -  creatinine within normal institutional limits

          -  Women of child-bearing potential must agree to use adequate contraception (hormonal or
             barrier method of birth control; abstinence) prior to study entry, for the duration of
             study participation, and for 90 days following completion of therapy. Should a woman
             become pregnant or suspect she is pregnant while participating in this study, she
             should inform her treating physician immediately.

          -  A female of child-bearing potential is any woman (regardless of sexual orientation,
             having undergone a tubal ligation, or remaining celibate by choice) who meets the
             following criteria:

          -  Has not undergone a hysterectomy or bilateral oophorectomy; or

          -  Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has
             had menses at any time in the preceding 12 consecutive months).

          -  Ability to understand and the willingness to sign a written informed consent.

        Exclusion Criteria:

          -  Undiagnosed vaginal bleeding

          -  Abnormal results from endometrial biopsy

          -  Presence of ovarian cysts ≥ 3 cm

          -  Pregnancy

          -  Refusal to adhere the birth control strategy of the study (use of a combination of a
             condom and a vaginal sponge during each intercourse while on ulipristal, plus one
             month before the onset and one month after the completion of ulipristal therapy)

          -  Women taking digoxin, dabigatran or etexilate due to interference of ulipristal
             acetate with the concentration of these substances bound by plasma proteins.

          -  Women taking moderate to potent inducers of hepatic metabolism (e.g. erythromycin,
             ketoconazole, ritonavir, nefazodone).

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to Ulipristal.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             pulmonary, cardiac, renal, hepatic or thromboembolic disease, infection, symptomatic
             congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric
             illness/social situations that would limit compliance with study requirements.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Serdar Bulun</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University, Northwestern Memorial Hopsital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University, Prentice Women's Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2014</study_first_submitted>
  <study_first_submitted_qc>August 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2014</study_first_posted>
  <last_update_submitted>September 27, 2016</last_update_submitted>
  <last_update_submitted_qc>September 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Serdar Bulun</investigator_full_name>
    <investigator_title>Chair, Department of Obstetrics &amp; Gynecology</investigator_title>
  </responsible_party>
  <keyword>Endometriosis</keyword>
  <keyword>chronic pelvic pain</keyword>
  <keyword>dysmenorrhea</keyword>
  <keyword>dyschezia</keyword>
  <keyword>bleeding</keyword>
  <keyword>ulipristal</keyword>
  <keyword>progesterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
    <mesh_term>Pelvic Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

